Skip to main
ACIU

AC Immune (ACIU) Stock Forecast & Price Target

AC Immune (ACIU) Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

AC Immune SA is making significant strides in the development of its neurodegenerative disease therapies, particularly through its innovative NLRP3 program, which could attract expanded interest pending positive EVOKE trial results for Alzheimer’s Disease patients. The promising performance of PD active immunotherapy ACI-7104.056, which has shown a 20-fold increase in antibodies against pathogenic variants of alpha-synuclein, along with stabilization of neurofilament light chain levels, suggests a favorable trajectory for future therapeutic efficacy and safety. Furthermore, the anticipated plaque removal data for ACI-24 could serve as a pivotal catalyst, potentially positioning this immunotherapy as a leading option for high-risk, pre-symptomatic Alzheimer's patients.

Bears say

AC Immune SA reported a significant net operating loss of CHF 16.2 million for the recent quarter, indicating ongoing financial challenges as it advances its clinical pipeline. The company also faced a net loss of CHF 70.4 million for the fiscal year 2025, with a basic and diluted earnings per share (EPS) of (0.70), reflecting its struggle to achieve profitability amid extensive research and development expenses. Additionally, the firm confronts inherent industry risks, including potential negative clinical trial results, regulatory uncertainties, and complications in navigating price-sensitive commercial markets.

AC Immune (ACIU) has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of AC Immune and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About AC Immune (ACIU) Forecast

Analysts have given AC Immune (ACIU) a Strong Buy based on their latest research and market trends.

According to 2 analysts, AC Immune (ACIU) has a Strong Buy consensus rating as of Apr 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $10, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $10, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

AC Immune (ACIU)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.